Harpoon Therapeutics, Inc. Company Profile

10:15 EST 16th December 2018 | BioPortfolio

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting drug discovery platform called TriTAC (tri-specific T-cell activating construct) to unleash the targeted cell-killing properties of a patient's own immune system through T-cell activation. This approach is being optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit

News Articles [709 Associated News Articles listed on BioPortfolio]

Harpoon Therapeutics Appoints Natalie Sacks Chief Medical Officer

Natalie Sacks has joined Harpoon Therapeutics as chief medical officer. Sacks comes to South San Francisco, CA-based Harpoon from Aduro Biotech (NASDAQ: ADRO) where she was chief medical officer. Harp...

Harpoon Therapeutics Adds Holger Wesche, Georgia Erbez to C-Suite

Harpoon Therapeutics has promoted Holger Wesche to chief scientific officer. Wesche had been senior vice president, research, of the South San Francisco, CA-based cancer immunotherapy developer. Harpo...

Harpoon Therapeutics treats first patient in Phase l trial of HPN424

Harpoon Therapeutics has treated the first patient in a Phase l clinical trial to investigate the safety, tolerability and pharmacokinetics...Read More... The post Harpoon Therapeutics treats first pa...

Harpoon Therapeutics secures $70m funds to advance immunotherapy programs

OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital,...

Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New ...

Harpoon’s Third Product Candidate is Slated for Clinical Development in 2019 Read more...

Funding round pulls in $70M for Harpoon

A round of Series C funding pulled in $70 million for immunotherapy company Harpoon Therapeutics, which has an ongoing early- -More- 

Executives On The Move: New CEOs At Perrigo And SanBio, CMOs At CardioVascular BioTherapeutics And Harpoon Therapeutics, And A Retirement At BTG

This week's company moves include a new CEO for Perrigo, while Harpoon Therapeutics and CardioVascular BioTherapeutics get new chief medical...   

Harpoon Therapeutics Appoints Ms. Julie Eastland, Biotech Industry Veteran, to Board of Directors

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engaging therapeutics, announced today that it has appointed Ms. Julie Eastla...

PubMed Articles [461 Associated PubMed Articles listed on BioPortfolio]

Hitting HIV's Harpoon.

The HIV-1 fusion peptide is a target for broadly neutralizing antibodies. In a recent issue of Nature Medicine, Xu et al. (2018) provide proof-of-concept that vaccination with fusion peptide followed...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is f...

Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver pot...

Harpoon Medical

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Harpoon Therapeutics, Inc." on BioPortfolio

We have published hundreds of Harpoon Therapeutics, Inc. news stories on BioPortfolio along with dozens of Harpoon Therapeutics, Inc. Clinical Trials and PubMed Articles about Harpoon Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harpoon Therapeutics, Inc. Companies in our database. You can also find out about relevant Harpoon Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record